CN111372949B - 抗trkb单克隆抗体及其使用方法 - Google Patents

抗trkb单克隆抗体及其使用方法

Info

Publication number
CN111372949B
CN111372949B CN201880069154.2A CN201880069154A CN111372949B CN 111372949 B CN111372949 B CN 111372949B CN 201880069154 A CN201880069154 A CN 201880069154A CN 111372949 B CN111372949 B CN 111372949B
Authority
CN
China
Prior art keywords
trkb
antibody
antigen
binding fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880069154.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111372949A (zh
Inventor
S·D·克罗尔
M·高
Y·胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CN202511361457.XA priority Critical patent/CN121181700A/zh
Publication of CN111372949A publication Critical patent/CN111372949A/zh
Application granted granted Critical
Publication of CN111372949B publication Critical patent/CN111372949B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880069154.2A 2017-11-30 2018-11-28 抗trkb单克隆抗体及其使用方法 Active CN111372949B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511361457.XA CN121181700A (zh) 2017-11-30 2018-11-28 抗trkb单克隆抗体及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592657P 2017-11-30 2017-11-30
US62/592,657 2017-11-30
PCT/US2018/062863 WO2019108662A1 (en) 2017-11-30 2018-11-28 Anti-trkb monoclonal antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511361457.XA Division CN121181700A (zh) 2017-11-30 2018-11-28 抗trkb单克隆抗体及其使用方法

Publications (2)

Publication Number Publication Date
CN111372949A CN111372949A (zh) 2020-07-03
CN111372949B true CN111372949B (zh) 2026-02-03

Family

ID=64665125

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880069154.2A Active CN111372949B (zh) 2017-11-30 2018-11-28 抗trkb单克隆抗体及其使用方法
CN202511361457.XA Pending CN121181700A (zh) 2017-11-30 2018-11-28 抗trkb单克隆抗体及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511361457.XA Pending CN121181700A (zh) 2017-11-30 2018-11-28 抗trkb单克隆抗体及其使用方法

Country Status (18)

Country Link
US (3) US11066474B2 (https=)
EP (1) EP3717514A1 (https=)
JP (2) JP7438937B2 (https=)
KR (1) KR20200090779A (https=)
CN (2) CN111372949B (https=)
AU (3) AU2018375340B2 (https=)
BR (1) BR112020006976A2 (https=)
CA (1) CA3083452A1 (https=)
CL (3) CL2020000855A1 (https=)
CO (1) CO2020004075A2 (https=)
EA (1) EA202090966A1 (https=)
IL (1) IL273538B2 (https=)
MA (1) MA51207A (https=)
MX (3) MX2020003550A (https=)
MY (1) MY203247A (https=)
PH (1) PH12020550409A1 (https=)
SG (1) SG11202002665UA (https=)
WO (1) WO2019108662A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use
IL310006A (en) * 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
JP7524158B2 (ja) * 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
US12559560B2 (en) * 2020-01-30 2026-02-24 Fred Hutchinson Cancer Center Antibody-based compositions for targeting tropomyosin receptor kinase B (TrkB) isoforms
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
TW202342494A (zh) 2022-03-30 2023-11-01 日商肽夢想股份有限公司 具有TrkB結合活性之肽複合物
CN120665203B (zh) * 2025-06-18 2026-03-27 广东优赛生物医药科技有限公司 一种药物组合物及其在治疗中枢性肥胖中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
CN101605556A (zh) * 2006-12-20 2009-12-16 瑞纳神经科学公司 治疗自体免疫疾病的trkb激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6225282B1 (en) 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2006133164A2 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
CA2712298C (en) 2008-01-17 2015-11-24 Irm Llc Improved anti-trkb antibodies
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
US10080745B2 (en) 2013-11-25 2018-09-25 The Regents Of The University Of California Santa Cruz Piericidin bacterial inhibitors
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
JP2019517787A (ja) * 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP4095161A1 (en) * 2017-03-15 2022-11-30 Tsinghua University Novel anti-trkb antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
CN101605556A (zh) * 2006-12-20 2009-12-16 瑞纳神经科学公司 治疗自体免疫疾病的trkb激动剂

Also Published As

Publication number Publication date
BR112020006976A2 (pt) 2020-10-13
CL2024002614A1 (es) 2025-01-24
AU2026200583A1 (en) 2026-02-19
MX2025001445A (es) 2025-03-07
EP3717514A1 (en) 2020-10-07
JP7438937B2 (ja) 2024-02-27
CL2020000855A1 (es) 2020-07-31
JP2024016204A (ja) 2024-02-06
US20240309100A1 (en) 2024-09-19
CN121181700A (zh) 2025-12-23
KR20200090779A (ko) 2020-07-29
IL273538B2 (en) 2024-10-01
US20220411515A1 (en) 2022-12-29
JP2021507677A (ja) 2021-02-25
US12037401B2 (en) 2024-07-16
IL273538B1 (en) 2024-06-01
SG11202002665UA (en) 2020-04-29
AU2018375340A1 (en) 2020-05-07
EA202090966A1 (ru) 2020-08-26
MA51207A (fr) 2020-10-07
CA3083452A1 (en) 2019-06-06
AU2018375340B2 (en) 2025-10-30
IL273538A (en) 2020-05-31
NZ763618A (en) 2025-05-02
AU2026200616A1 (en) 2026-02-19
MX2025001444A (es) 2025-03-07
WO2019108662A1 (en) 2019-06-06
MX2020003550A (es) 2020-08-03
MY203247A (en) 2024-06-19
CO2020004075A2 (es) 2020-08-31
CN111372949A (zh) 2020-07-03
US20190161551A1 (en) 2019-05-30
PH12020550409A1 (en) 2021-04-12
US11066474B2 (en) 2021-07-20
CL2024002612A1 (es) 2025-01-24

Similar Documents

Publication Publication Date Title
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP6923602B2 (ja) 抗アクチビンａ抗体及びその使用
CN111372949B (zh) 抗trkb单克隆抗体及其使用方法
JP6718482B2 (ja) ＧＦＲα３に対するヒト抗体およびその使用方法
EP2459592B1 (en) High affinity human antibodies to human angiopoietin-2
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
US8840894B2 (en) Antibodies to human GDF8
EA044580B1 (ru) Моноклональные анти-trkb антитела и способы их применения
HK1166806B (en) High affinity human antibodies to human angiopoietin-2
NZ716854B2 (en) Anti-activin a antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant